Want to see SG:8YY full AI Analyst Report?
Top Page
Biolidics Ltd.
(SGX:8YY)
Select Model
Select Model
Rating:42Neutral
Price Target:
S$0.03
▼(-20.00% Downside)
Action:Reiterated
Date:07/29/26
The score is primarily held down by weak financial performance—ongoing losses, negative free cash flow, and a balance sheet with limited equity cushion relative to debt despite a strong 2025 revenue rebound. Technicals also weigh on the score as the stock trades below all major moving averages, signaling a persistent downtrend. Valuation is constrained by a negative P/E (loss-making) and lack of dividend yield data.
Positive Factors
Sharp Revenue Rebound
The substantial 2025 revenue recovery indicates renewed demand or improved commercialization. If sustained, a larger revenue base could support operating leverage and improve the company’s ability to absorb its fixed diagnostic development and commercialization costs.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that the business has not yet achieved sustainable scale. Even with stronger revenue, continued losses can consume capital, constrain investment in diagnostics development and increase reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp Revenue Rebound
The substantial 2025 revenue recovery indicates renewed demand or improved commercialization. If sustained, a larger revenue base could support operating leverage and improve the company’s ability to absorb its fixed diagnostic development and commercialization costs.
Read all positive factors
Biolidics Ltd. (8YY) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$57.20M
Dividend YieldN/A
Average Volume (3M)412.95K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS GrowthN/A
CountrySG
Employees16
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolidics Ltd. Business Overview & Revenue Model
Company Description
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its busines...
How the Company Makes Money
Biolidics makes money primarily by selling diagnostic products and related solutions to customers such as clinical laboratories, hospitals, research institutions, and other healthcare or life-sciences users. Revenue is typically generated from (i)...
Biolidics Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.82M | 5.26M | 784.00K | 277.00K | 2.49M | 2.31M |
| Gross Profit | 2.09M | 1.94M | 187.00K | 146.00K | 1.16M | 483.00K |
| EBITDA | -2.63M | -3.65M | -3.03M | -1.16M | -8.50M | -4.58M |
| Net Income | -3.05M | -3.96M | -3.43M | -2.49M | -9.37M | -5.98M |
Balance Sheet | ||||||
| Total Assets | 5.59M | 5.08M | 4.67M | 682.00K | 6.09M | 11.42M |
| Cash, Cash Equivalents and Short-Term Investments | 494.00K | 557.00K | 295.00K | 183.00K | 5.03M | 3.96M |
| Total Debt | 378.00K | 2.41M | 1.75M | 2.02M | 3.01M | 4.25M |
| Total Liabilities | 3.77M | 3.56M | 2.94M | 2.67M | 7.78M | 9.09M |
| Stockholders Equity | 1.83M | 1.53M | 1.73M | -1.99M | -1.69M | 2.33M |
Cash Flow | ||||||
| Free Cash Flow | 391.00K | -360.00K | -2.32M | -1.97M | -3.16M | -5.20M |
| Operating Cash Flow | 393.00K | -360.00K | -2.31M | -1.97M | -3.06M | -4.64M |
| Investing Cash Flow | -2.00K | 0.00 | -5.00K | -2.69M | 5.00K | -860.00K |
| Financing Cash Flow | -210.00K | 623.00K | 2.36M | -200.00K | 4.18M | -1.15M |
Biolidics Ltd. Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.05
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
34.41
Neutral
-3.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.41 is Neutral, neither overbought nor oversold. The STOCH value of -3.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8YY.
Biolidics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:8YY
Biolidics Ltd.
0.03
0.01
43.48%
SG:P8A
Cordlife Group
0.13
-0.07
-34.50%
SG:40T
ISEC Healthcare Ltd
0.31
-0.04
-10.92%
SG:546
Medtecs International Corporation Ltd.
0.11
>-0.01
-8.13%
SG:584
AJJ Medtech Holdings Limited
0.01
0.00
0.00%
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.03
<0.01
14.81%
Biolidics Ltd. Corporate Events
Embracing Future Holdings Extends Deal Deadlines and Aligns Share Plan With New Brand
Jun 30, 2026
Embracing Future Holdings Limited, formerly Biolidics Limited, is a Singapore-based holding company overseeing a group of subsidiaries and a performance share plan. The rebranding underscores a shift away from the Biolidics name toward a broader c...
Embracing Future Holdings Shareholders Approve Accounts, Board Mandates and New Share Issue Authority
May 22, 2026
Embracing Future Holdings Limited held its annual general meeting in Singapore on 29 April 2026, where shareholders adopted the audited financial statements for the year ended 31 December 2025 and approved directors’ fees of up to S$150,000 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.